Virtual Research Ecosystems

The 21st Century BrainTrust® (21CBT) is a virtual research platform that promotes brain health through innovation. Think new digital biomarkers, mapped using the power of self-administered cognitive testing as a sensitive, early screening tool for all brain traumas, Alzheimer’s and related dementias. 21CBT promotes novel technologies that offer low-cost screening capabilities for future prevention trials to facilitate enrollment, as well as exploratory trial endpoints. 21CBT is a collaboration of the Geoffrey Beene Foundation Alzheimer’s Initiative, BrightFocus Foundation, Cleveland Clinic/Lou Ruvo Brain Institute and UsAgainstAlzheimer’s.


21CBT Award

A 21CBT Innovations Award ($50,000), by the 21st Century BrainTrust®, was offered in Round Two of the 2013 Geoffrey Beene Global NeuroDiscovery Challenge on sex-based differences in Alzheimer’s disease, in support of the WomenAgainstAlzheimer’s Network. Four finalists in this global online research competition were named in Round One.

The Challenge exceeded expectations in terms of both scientific interest and global outreach with 65 participating countries and final submissions from 23 countries.

Crowdvoting by the scientific community and citizen scientists worldwide determined Round Two winners of $50,000 21CBT Innovation Award. Learn more…



There is currently very little education and/or curriculum offered about Alzheimer’s, caretaking
for Alzheimer’s patients, or impact on family members and friends. In the United States, more
than 5 million people have Alzheimer’s, and there are 3x as many caregivers. In 2013, 15.5
million caregivers provided an estimated 17.7 billion hours of unpaid care. In New York State
alone, 23% of caretakers are under the age of 18.

Download the Alzheimer’s Adjustable Curriculum Prototype in Word

Alzheimer’s is in our high schools – in the form of kids caring for their parents with early-onset
AD, and witnessing their grandparents live with and die from it. We cannot afford to delay
education about Alzheimer’s any longer. We hope this serves as a basis for Alzheimer’s
curriculums for schools and organizations throughout the country, and offers support to students
and educators.

Download the Alzheimer’s Adjustable Curriculum Prototype in PDF

View the Curriculum in GoogleDocs



Spotlight on Research

The 21st Century BrainTrust® (21CBT) mission is to stimulate a three-way connection between a new generation of technology innovation, the scientific community, and an engaged public to advance brain health and prevention trials. The scientific community has only begun to understand initial, pre-symptomatic disease progression and potential therapeutic options.

21CBT focuses on this relatively new field of research.



The Geoffrey Beene Foundation Alzheimer’s Initiative led the formation of the 21st Century BrainTrust® in 2012 with three other non-profits – BrightFocus® Foundation, UsAgainstAlzheimer’s, and scientific partner Cleveland Clinic/Lou Ruvo Brain Institute.

The coalition was named the winner of a $100,000 developmental prize as part of the Sanofi US Partners in Patient Health Collaborate | Activate Innovation Challenge. The team was selected for the prize from among nearly 300 proposals submitted to the Challenge.

BrightFocus® Foundation

BrightFocus® Foundation is a nonprofit organization supporting research and providing public education to help eradicate brain and eye diseases, including Alzheimer’s disease, macular degeneration, and glaucoma. We are working to save mind and sight. BrightFocus® is at the forefront of brain and eye health, advancing early-stage, investigator-initiated research around the world.

USAgainstAlzheimer’s Network

USAgainstAlzheimer’s Network is a leader in marshaling political will toward combating Alzheimer’s. One of only 12 non-governmental members of the National Alzheimer’s Project Act Advisory Council, USAgainstAlzheimer’s is also co-convener of the Global CEO Initiative on Alzheimer’s Disease, and Leaders Engaged on Alzheimer’s Disease (LEAD), a coalition of 40 organizations from the government, business and civic sectors.



21CBT Scientific Advisory Board

  • Moses Chao
    Professor Cell Biology, NYU School of Medicine, Chairman, Society of Neuroscience
  • Deepak Chopra
    Founder, The Chopra Foundation
  • Jeffrey Cummings
    Director of Cleveland Clinic/Lou Ruvo Center for Brain Health
  • William Haseltine
    Founder  Human Genome Sciences
  • Bradley Hyman
    Director, Alzheimer’s Disease Research Center Harvard Medical School
  • Philip Low
    Chief Executive Officer, NeuroVigil
  • Mark Murko
    Founder, Disruptive Biomedical LLC
  • Alan Russell
    Director of the McGowan Institute of Regenerative Medicine; Editor-n-Chief, Disruptive Science and Technology
  • Jerre Stead
    Chief Executive Officer, HIS
  • Rudi Tanzi
    Professor, Harvard/MGH and Principal, Alzheimer’s Whole Genome Sequencing Cure Alzheimer’s Fund
  • Eric Topol
    Vice Chairman, West Wireless Health Institute
  • Michael Weiner
    Principal Investigator Alzheimer’s Disease Neuroimaging Initiative (ADNI)
  • Pascale Witz
    CEO, GE Medical Diagnostics

2013 Geoffrey Beene Global NeuroDiscovery Challenge Judging Panel

  • Marietta Anthony, PhD
    Consultant in Women’s Health Research
  • Howard Fillit, MD
    Founding Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation
  • Freda Lewis-­Hall, MD
    Executive Vice President and Chief Medical Officer, Pfizer
  • Florence Haseltine, MD, PhD
    IT Consultant, Founder, Society for Women’s Health Research
  • Lenore Launer, PhD
    Chief of the Neuroepidemiology Section, NIA
  • Michelle Mielke, PhD
    Associate Professor of Epidemiology, Mayo Clinic
  • Peter Rabins, MD, MPH
    Professor, Department of Psychiatry and Director of the Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins Medicine
  • Alan Russell, PhD
    Founding Director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine, Carnegie Mellon University
  • Janine Clayton, MD
    Director of Women’s Health, NIH (ex-officio capacity)